Your browser doesn't support javascript.
Protection against Omicron BA.1/BA.2 severe disease 0-7 months after BNT162b2 booster.
Amir, Ofra; Goldberg, Yair; Mandel, Micha; Bar-On, Yinon M; Bodenheimer, Omri; Freedman, Laurence; Alroy-Preis, Sharon; Ash, Nachman; Huppert, Amit; Milo, Ron.
  • Amir O; Technion - Israel Institute of Technology, Haifa, Israel.
  • Goldberg Y; Technion - Israel Institute of Technology, Haifa, Israel. yairgo@technion.ac.il.
  • Mandel M; The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Bar-On YM; Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Bodenheimer O; Israel Ministry of Health, Jerusalem, Israel.
  • Freedman L; The Bio-statistical and Bio-mathematical Unit, The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Ramat Gan, Israel.
  • Alroy-Preis S; Israel Ministry of Health, Jerusalem, Israel.
  • Ash N; Israel Ministry of Health, Jerusalem, Israel.
  • Huppert A; The Bio-statistical and Bio-mathematical Unit, The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Ramat Gan, Israel.
  • Milo R; The Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Commun Biol ; 6(1): 315, 2023 03 23.
Article in English | MEDLINE | ID: covidwho-2249457
ABSTRACT
Following evidence of waning immunity against both infection and severe disease after 2 doses of the BNT162b2 vaccine, Israel began administering a 3rd BNT162b2 dose (booster) in July 2021. Recent studies showed that the 3rd dose provides a much lower protection against infection with the Omicron variant compared to the Delta variant and that this protection wanes quickly. However, there is little evidence regarding the protection of the 3rd dose against Omicron (BA.1/BA.2) severe disease. In this study, we estimate the preservation of immunity from severe disease up to 7 months after receiving the booster dose. We calculate rates of severe SARS-CoV-2 disease between groups of individuals aged 60 and above, comparing those who received two doses at least 4 months previously to those who received the 3rd dose (stratified by the time from vaccination), and to those who received a 4th dose. The analysis shows that protection conferred by the 3rd dose against Omicron severe disease did not wane over a 7-month period. Moreover, a 4th dose further improved protection, with a severe disease rate approximately 3-fold lower than in the 3-dose cohorts.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Commun Biol Year: 2023 Document Type: Article Affiliation country: S42003-023-04669-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Commun Biol Year: 2023 Document Type: Article Affiliation country: S42003-023-04669-6